Q2 2026 RPG Life Sciences Ltd Earnings Call Transcript
Key Points
- RPG Life Sciences Ltd (BOM:532983) reported a robust growth of 17.2% in its domestic formulation business for Q2 FY26, significantly outpacing the Indian pharmaceutical market growth of 7.7%.
- The company advanced its IPM ranking by 6 places, moving from 62 to 56, driven by volume expansion, strategic brand building, and disciplined execution.
- RPG Life Sciences Ltd's largest brand, Naprosyn, grew 16% year-over-year in H1 FY26 and is on track to become the company's first INR100 crore brand.
- The company remains debt-free with a high cash surplus of approximately INR223 crores, despite significant CapEx investments in modernizing and enhancing its plants.
- RPG Life Sciences Ltd was recognized as the leading mid-corporate of India 2025 by Dun & Bradstreet, reflecting its strong operational and quality focus.
- The company faced headwinds in its API business due to a fire incident at its factory in January, leading to a sales loss of INR16 crores.
- Gross margin compression was noted, partially due to reliance on third-party suppliers and the inability to produce captive API following the fire incident.
- RPG Life Sciences Ltd does not currently have any exposure to the U.S. market, which could limit its growth opportunities in one of the largest pharmaceutical markets.
- There is ongoing margin pressure in the MABs (monoclonal antibodies) segment due to increased competition and price erosion.
- Despite the company's strong domestic performance, the international formulation business only grew by 7.0% in Q2, indicating slower growth compared to the domestic market.
Ladies and gentlemen, good day, and welcome to the RPG Life Sciences Q2 FY26 conference call hosted by Dolat Capital. (Operator Instructions) I now hand the conference over to Ms. Candice Pereira from Dolat Capital. Thank you, and over to you, ma'am.
Thank you, Ashok. Good evening, everyone. I Candice Pereira on behalf of Dolat Capital, welcome you all to the Q2 FY26 Earnings Call of RPG Life Sciences Limited. I would like to thank the management for giving us this opportunity to host the call.
Today, from the management team, we have with us Mr. Ashok Nair, Managing Director; and Mr. Vishal Shah, CFO. I now hand over the call to the management for the opening remarks. Over to you, sir.
Thank you, Ms. Pereira. Thank you. So a warm welcome, and thank you for joining us today. It's a pleasure to engage with you and share our quarter 2 and H1 updates.
Just to let you
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
